Stelara C1q Binding Assays

BioOutsource offers an off-the-shelf Stelara C1q binding assay to support Stelara biosimilar manufacture, process development, and characterization and comparability studies. We offer industry leading Stelara comparability and Stelara characterization services and can be adapted to function as qualified or validated cGMP lot release and stability studies for your product.

The complement system complements the ability of antibodies to clear pathogens and cancerous cells from the body. It is a collection of small proteins present in the blood that typically circulate as inactive precursors. The classical pathway is triggered by activation of the C1-complex which is composed of single C1q molecule with 2 molecules of C1r and C1s and occurs when C1q binds multiple IgG molecules complexed with antigen; this has the potential to lead to a signalling cascade culminating in complement-dependent cytotoxicity (CDC).

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.